Drug Detail

Information about Entrectinib

Generic Name	Entrectinib
IND	RXDX-101
Brand Name (US)
Manufacturer	Ignyta
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications	NTRK1/2/3, ROS1, or ALK gene rearrangement
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	TRK Inhibitor

Potentially targets ETV6/ NTRK3 fusion mutations.

Indications include cancers with NTRK1/2/3, ROS1, or ALK gene rearrangement including Sarcomas and Adult Solid Tumors

Links
	Selleckchem

	Ignyta AACR 2016

	ESMO Sept., 2015

	Transcriptome sequencing identifies ETV6–NTRK3 as a gene fusion involved in GIST

	SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis

Trials of this drug
	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Trial results

Search for this drug/combination in:

ClinicalTrials.gov